Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis
Abstract Observational studies have suggested that HER2 inhibition with trastuzumab may be associated with an increased incidence of intracranial metastatic disease (IMD) due to its ability to prolong survival. We hypothesized that prolonged survival associated with dual-agent HER2 inhibition may be...
Saved in:
Main Authors: | Anders Wilder Erickson, Steven Habbous, Christianne Hoey, Katarzyna J. Jerzak, Sunit Das |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/fbb56a6898a446b5a5e73ebedbd73af9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
by: Laura Pizzuti, et al.
Published: (2021) -
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
by: Advani P, et al.
Published: (2015) -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
by: Fara Brasó-Maristany, et al.
Published: (2020) -
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
by: Salkeni MA, et al.
Published: (2021) -
Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
by: Abdel Kader Y, et al.
Published: (2013)